As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.
Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity.A group that ...
Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition ...
Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...
Eli Lilly has reduced the price of its weight-loss drug, Zepbound, to combat competition from compounding pharmacies and Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results